A Phase 1 interventional study of JYB1904 and Omalizumab in Healthy, sponsored by Jemincare. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-27.
Sponsored by Jemincare · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This phase Ia study is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904, an anti-immunoglobulin E (IgE) antibody, in healthy Chinese subjects.
This first-in-human study with a dose-escalation design is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904 in healthy Chinese subjects.
The sequential dose levels (sample size) of JYB1904 are set at five different dose, with additional two JYB1904 placebo subjects in each group. The active comparator is omalizumab (Xolair).
Dosage and administration: single-dose; subcutaneous injection in the deltoid region of the upper arm.
Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single-dose; subcutaneous injection in the deltoid region of the upper arm.
Drug: JYB1904 · Drug: JYB1904 Placebo
single-dose; subcutaneous injection in the deltoid region of the upper arm.
Drug: Omalizumab
Dosage form: injection, solution; Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Dosage form: injection, powder, lyophilized, for solution; Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Also known as: Xolair
Dosage form: injection, solution; Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Adverse events (AEs)
Incidence and features of AEs assessed by CTCAE v5.0
Time frame: Baseline through 168 days post-dose
Serum concentrations of JYB1904 and Omalizumab
Serum JYB1904 and Omalizumab assessed by pre-specified methods, and related pharmacokinetic parameters analysis
Time frame: Baseline through 168 days post-dose
Serum concentrations of total/free IgE
Serum total/free IgE assessed by a pre-specified method, and related pharmacodynamic parameters analysis
Time frame: Baseline through 168 days post-dose
Serum concentrations of anti-drug antibody (ADA) and neutralizing antibody (Nab)
Serum ADA and Nab assessed by pre-specified methods, and related immunogenic features analysis
Time frame: Baseline through 168 days post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jan 2023, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ozureprubart